Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
about
N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart diseasePlasma brain natriuretic peptide concentrations in patients with valvular heart diseaseLiving with pulmonary hypertension: unique insights from an international ethnographic study.Natriuretic Peptide testing in primary careCardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies.How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic reviewClinical burden and health service challenges of chronic heart failureScreening for left ventricular dysfunction: a step too far?Screening for treatable left ventricular abnormalities in diabetic patients.Usefulness of N-terminal Pro-brain Natriuretic Peptide and Myocardial Perfusion in Asymptomatic Adults (from the Multi-Ethnic Study of Atherosclerosis).Survival differences between heart failure in general practices and in hospitals.N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure.Relation between left ventricular contractile reserve during low dose dobutamine echocardiography and plasma concentrations of natriuretic peptidesDiagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general populationAllopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure.B-type natriuretic peptide measurement in heart failure.Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population.Diagnosis and assessment of the heart failure patient: the cornerstone of effective management.The prognostic value of anemia, right-heart catheterization and neurohormones in chronic heart failure.Systolic dysfunction portends increased mortality among those waiting for renal transplantIdentification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide.Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies.Heart failure epidemiology: European perspective.Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?Treatment strategies for the prevention of heart failurePrognosis of patients with heart failure and reduced ejection fraction in China.Do optimal prognostic thresholds in continuous physiological variables really exist? Analysis of origin of apparent thresholds, with systematic review for peak oxygen consumption, ejection fraction and BNPCan we use B-type natriuretic peptides to monitor patients with heart failure?B-type natriuretic peptides in heart failure.Novel biomarkers in human terminal heart failure and under mechanical circulatory support.Heart transplantation in adults with end-stage congenital heart disease.Development and initial validation of a simple clinical decision tool to predict the presence of heart failure in primary care: the MICE (Male, Infarction, Crepitations, Edema) rule.Prognostic value of biological markers in myocardial infarction patients.A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms.Current Role of Blood and Urine Biomarkers in the Clinical Care of Adults with Congenital Heart Disease.The prognosis of impaired left ventricular systolic function and heart failure in a middle-aged and elderly population in an urban population segment of Copenhagen.Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome.Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy.N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis.
P2860
Q24607043-15B0C4AE-F173-40B4-A76A-A39C409EF1EEQ28603050-2250EC6A-0B59-4EB7-88BE-8DE225120E97Q30578342-F8351A8D-7741-43E9-816B-1FABD2E5729AQ33572286-E812C27A-41B1-4A46-804A-903B630FFC58Q33578171-DC64E578-840D-4C59-96D8-90DB0C5F4A1DQ33932889-A9D31FAC-ACD9-4BB2-9D86-8C30801B15A1Q34035122-A1895513-9522-4F9B-B69F-47DD82A81510Q34816965-EAAC5024-A6BC-4ACF-B8F7-31A4DE6E3BC7Q35116162-5ED1A10B-B745-4EE7-B8E6-A2412644D799Q35554304-871B47FB-48A0-42A9-A66E-65CDEB42791DQ35574257-92FFCBA3-6496-43A0-BFC6-E6E1E0697800Q35581367-0C418C98-C5F6-4BFC-AF7F-B8AB11F668B3Q35582086-8EC1BA9D-BFDC-4075-AE6D-914B6CB4C134Q35582125-E2926CEE-ADF2-460B-A07E-ECAE1646B2CAQ35584237-7C309FBE-5C8F-41A1-B4E7-59207F60D621Q35717608-62376F35-D95D-4EEB-8AC4-710D55D92CC9Q35911696-E9F403B7-8ED7-4484-AC52-A3C722487AE6Q36014317-4C8F6ABE-F749-41D3-A851-D1135932D237Q36046578-DED5112F-0C49-4B4A-850C-630C6F4051DDQ36352015-41D3A4F8-D32F-41C2-8D6F-4D87C9EBF555Q36677673-EC9019B0-E6C1-4FFA-9F61-448C64C610A8Q36707626-CAB238B3-4F3F-46F6-A3CC-04A3C66B003AQ36902446-99234995-A7CC-45F1-958F-6058E39B520DQ36928514-74548A0F-01F9-46AC-AD59-E5D9FF31913BQ37097127-51EA4637-D280-4808-A34F-F73431C519FFQ37297198-A2EDFFD3-067E-49BF-8A86-A462FFC2CD04Q37313229-3828795A-9A03-4AF4-A7E4-892CA116CE7FQ37520567-9CDB90DD-5A78-4A0E-9B07-4DE925E11596Q37755067-7A3F1940-4AA5-4EB3-B4A0-AF6AC748239EQ37755096-FB453E36-DA2B-4D89-875A-7E4A561C7AFEQ37894731-396B1288-2714-4E89-973F-C80721C0D8E6Q37993155-65E283BB-C416-411C-8095-4216655C3AF6Q38020022-3D972091-8E8A-49C9-999F-D415B1BB5182Q38188531-9AFB1852-8F56-46BB-BC69-11125A41F088Q38542681-3A196C7C-0E29-4D1A-B197-4CA3C2104275Q38825516-1577CA37-57FF-41C8-A842-023412D33D47Q39691778-393C6C5D-310E-43D9-BCBF-A7C5A251E614Q39734086-ABEF27D5-03E8-4A03-B665-8B031CB4DA35Q40377138-4BA69966-24FF-45A8-8EE4-A6A58C0C8C34Q40528931-DB4B2BC1-F5EC-4A9E-B1FE-2E702FB85300
P2860
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@ast
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@en
type
label
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@ast
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@en
prefLabel
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@ast
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@en
P2093
P2860
P356
P1433
P1476
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
@en
P2093
Cunningham AD
McDonagh TA
McMurray JJ
Morrison CE
P2860
P356
10.1136/HEART.86.1.21
P407
P577
2001-07-01T00:00:00Z